Faculty

Needs Statement

Kentucky State Senate Bill 32 (2017) mandated that drug conviction data be made available in KASPER effective July 1, 2018.  Education to prescribers on how to interpret this data in the context of patient care and opioid prescribing is needed to prevent unintended consequences.

Target Audience

This activity is designed for prescribers of controlled substances including physicians, nurse practitioners, dentists, and any other interested healthcare professionals.

Objectives

Kentucky Senate Bill 32 and Drug Conviction Data in KASPER: What Have We Learned?
Upon completion of this education activity, participants will be able to:

• Discuss implications of SB 32 that made drug conviction data available in KASPER effective July 1, 2018
• Review results of Kentucky prescriber and dispenser survey on intent to use drug conviction data in KASPER
• Assess current data regarding the use of drug conviction data in KASPER by prescribers and dispensers 

Drug Conviction Data in KASPER: What Does it Mean?
Upon completion of this education activity, participants will be able to:

• Describe the types of drug-related charges in Kentucky
• Review example drug conviction data and describe its content and interpretation
• Identify limitations of drug conviction data
• Evaluate nuances of interpreting drug conviction data and legal implications

Drug Conviction Data in KASPER: What Should I Do?
Upon completion of this education activity, participants will be able to:

• Discuss the impact of criminal conviction data on prescribers’ attitudes and resulting patient health outcomes
• Use example vignettes to interpret drug conviction data in the context of patient care
• Identify strategies for making sound decisions when prescribing controlled substances to prevent unintended consequences

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0120-H1.5-UK20b

ACGME Competencies

• Patient care
• Medical knowledge

Other
UK Healthcare CECentral certifies this activity for 1.50 hours of participation.

CDE
This online course meets regulatory requirements for 1.50 hours credit as permitted by 201 KAR 8:532 for dentists and 201 KAR 8:562 for dental hygienists.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.50 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Michelle Lofwall, MD (Speaker) for this educatonal event has relevant financial relationships with commercial interests as follows:
Camurus - Speaker - Honorarium
Titan Pharmaceuticals, Inc. - Consultant - Consultant Fee

All of the relevant financial relationships listed for these individuals have been mitigated.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This project was supported by Grant No. 2017-PM-BX-K026 (Data-Driven Responses to Prescription Drug Misuse in Kentucky) awarded by the Bureau of Justice Assistance (BJA) to the Kentucky Injury Prevention and Research Center as bona fide agent for the Kentucky Department for Public Health.

The BJA is a component of the Department of Justice’s Office of Justice Program, which includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the Office of Victims Crime, and the SMART Office.

Viewpoints or opinions in these programs are those of the authors and do not necessarily represent the official position or policies of the US Department of Justice.